Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: How curable is high-risk disease?

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 5, 2011, Pages 1279-1285

  Zapatero, Almudena ^a   García Vicente, Feliciano ^a   Martín De Vidales, Carmen ^a   Cruz Conde, Alfonso ^a   Ibáñez, Yamile ^a   Fernández, Inmaculada ^a   Rabadán, Mariano ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Androgen deprivation; Conformal radiotherapy; Dose escalation; High risk prostate cancer; Prostate cancer

Indexed keywords

ANDROGEN DEPRIVATION; CONFORMAL RADIOTHERAPY; DOSE ESCALATION; PROSTATE CANCER; PROSTATE CANCERS;

DISEASES; DOSIMETRY; ENDOCRINOLOGY; HORMONES; MULTIVARIANT ANALYSIS; PATIENT MONITORING;

RADIOTHERAPY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CONSENSUS; DISEASE FREE SURVIVAL; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HEMATURIA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE;

AGED; ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 81855194715     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.07.1975     Document Type: Article

References (36)

1. A. Pollack, G.K. Zagars, and G. Starkschall Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105 (Pubitemid 34787842)
2. M.J. Zelefsky, Y. Yamada, and Z. Fuks Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes Int J Radiat Oncol Biol Phys 71 2008 1028 1033
3. D.A. Kuban, S.L. Tucker, and Y.L. Dong Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74 (Pubitemid 350251041)
4. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial JAMA 294 2005 1233 1239 (Pubitemid 41352111)
5. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487 (Pubitemid 46805903)
6. S.T. Peeters, W.D. Heemsbergen, and P.C. Koper Dose response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996 (Pubitemid 46622106)
7. M. Roach 3rd, K. Bae, and J. Speight Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591 (Pubitemid 351264352)
8. M. Bolla, L. Collette, and G. Van Tienhoven Ten-year results of long-term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: A phase III EORTC study Int J Radiat Oncol Biol Phys 72 2008 S30 S31
9. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290 (Pubitemid 40470408)
10. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
11. C.A. Lawton, M. DeSilvio, and M. Roach 3rd An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions Int J Radiat Oncol Biol Phys 69 2007 646 655 (Pubitemid 47418390)
12. A. Zapatero, F. Valcárcel, and F.A. Calvo Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study J Clin Oncol 23 2005 6561 6568 (Pubitemid 46190249)
13. A. Zapatero, P. Rios, and A. Marin Dose escalation with three-dimensional conformal radiotherapy for prostate cancer. Is more dose really better in high-risk patients treated with androgen deprivation? Clin Oncol (R Coll Radiol) 18 2006 600 607 (Pubitemid 44309267)
14. A.D. Vassil, E.S. Murphy, and C.G. Robinson Androgen deprivation therapy in patients treated with external beam radiotherapy for high-risk prostate cancer in the PSA era (Abstr.) Int J Radiat Oncol Biol Phys 75 Suppl. 1 2009 S82
15. S. Yalamanchi, N.N. Stone, and R.G. Stock Impact of hormonal therapy in the management of intermediate risk prostate cancer treated with permanent prostate brachytherapy and external beam irradiation (Abstr.) Int J Radiat Oncol Biol Phys 75 Suppl. 1 2009 S83
16. P.L. Nguyen, M.H. Chen, and W.J. Catalona Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors Int J Radiat Oncol Biol Phys 73 2009 659 664
17. A. Zapatero, A. Guerrero, and X. Maldonado Long-term versus short-term androgen deprivation combined with high-dose radiotherapy for localized prostate cancer: A Spanish multicenter phase III trial (Abstr.) Clin Oncol 28 2010 (suppl; abstr e15036)
18. A. Zapatero, R. Mnguez, and S. Nieto Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: What can they teach us? Eur Urol 55 2009 902 910
19. M. Roach III, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
20. D.R. Cox Regression models and life tables J R Stat Soc (B) 34 1972 187 220
21. S. Kumar, M. Shelley, and C. Harrison Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer Cochrane Database Syst Rev 2006 (4):CD006019
22. W.W. Wong, S.A. Vora, and S.E. Schild Radiation dose escalation for localized prostate cancer intensity-modulated radiotherapy versus permanent transperineal brachytherapy Cancer 115 2009 5596 5606
23. E.F. Miles, and W.R. Lee Hypofractionation for prostate cancer: A critical review Semin Radiat Oncol 18 2008 41 47 (Pubitemid 350235955)
24. M. Perrotti, T. Doyle, and P. Kumar Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10) Urol Oncol 26 2008 276 280 (Pubitemid 351608579)
25. H.T. Chung, P. Xia, and L.W. Chan Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT Int J Radiat Oncol Biol Phys 73 2009 53 60
26. S.L. Liauw, W.M. Stadler, and D. Correa Dose-escalated radiotherapy for high-risk prostate cancer: Outcomes in modern era with short-term androgen deprivation therapy Int J Radiat Oncol Biol Phys 77 2010 125 130
27. S.A. Vora, W.W. Wong, and S.E. Schild Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity modulated radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 68 2007 1053 1058 (Pubitemid 47048576)
28. A. Zapatero, F. Garcia-Vicente, and I. Modolell Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: Dose-volume effect Int J Radiat Oncol Biol Phys 59 2004 1343 1351 (Pubitemid 38954056)
29. P.L. Ross, C. Gerigk, and M. Gonen Comparisons of nomograms and urologists' predictions in prostate cancer Semin Urol Oncol 20 2002 82 88 (Pubitemid 34522545)
30. M.W. Kattan, M.J. Zelefsky, and P.A. Kupelian Pretreatment nomogram for predicting the outcome of 3-dimensional conformal radiotherapy in prostate cancer J Clin Oncol 18 2000 3352 3359
31. A.W. Partin, J. Yoo, and H.B. Carter The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer J Urol 150 1993 110 114 (Pubitemid 23175983)
32. M. Roach, J. Lu, and M.V. Pilepich Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials Int J Radiat Oncol Biol Phys 47 2000 609 615 (Pubitemid 30317478)
33. L. Potters, M. Roach III, and B.J. Davis Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable Int J Radiat Oncol Biol Phys 76 2010 1061 1065
34. A. Lopergolo, and N. Zaffaroni Biomolecular markers of outcome prediction in prostate cancer Cancer 115 13 Suppl. 2009 3058 3067
35. M. Roach, F. Waldman, and A. Pollack Predictive models in external beam radiotherapy for clinically localized prostate cancer Cancer 115 13 Suppl. 2009 3112 3120
36. D.I. Quinn, S.M. Henshall, and R.L. Sutherland Molecular markers of prostate cancer outcome Eur J Cancer 41 2005 858 887 (Pubitemid 40461690)